Navigation Links
WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year
Date:11/30/2009

SHANGHAI, Nov. 30 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical-device research and development outsourcing company with operations in China and the United States, announced that it had been selected to the Deloitte Technology Fast 50 China 2009 list for the fifth consecutive year. The list recognizes the 50 fastest-growing companies in China's technology, media, and telecommunications industries based on revenue growth rates over the previous three years. WuXi PharmaTech is one of only two companies to have won this award for five consecutive years.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

"This recognition is a credit to the dedication and hard work of our employees and the high quality of service they deliver," said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "Through expansion of our capabilities and capacity, both in China and the United States, we are building a broad and fully integrated platform of pharmaceutical R&D services for our customers. We are confident that our continued investment in this platform will generate strong future revenue growth."

    For more information, please contact:

    WuXi PharmaTech (Cayman) Inc.

     Ronald Aldridge (for investors)
     Director of Investor Relations
     Tel:   +1-201-585-2048
     Email: ir@wuxiapptec.com

     Stephanie Liu (for the media)
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +86-21-5046-4362
     Email: pr@wuxiapptec.com

SOURCE WuXi PharmaTech
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline
2. WuXi PharmaTech Announces Second-Quarter 2009 Results
3. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting
4. WuXi PharmaTech Schedules Second-Quarter 2009 Earnings Release
5. WuXi PharmaTech Receives Award from BASF
6. WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise
7. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
8. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
9. WuXi PharmaTech to Present at Third Annual Jefferies Healthcare Conference
10. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
11. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... NYSE: SNY) today announced that the Companies intend to ... pediatric disease priority review voucher in connection with the ... review voucher entitles the holder to designate a BLA ... review from the filing date instead of the standard ...
(Date:7/30/2014)... 30, 2014  Replikins Ltd. today released new data ... virus. Before the current outbreaks, the mean Ebola Reston ... acids) between 1995 and 2002 was 1.1; the mean ... and sixteen-fold in 2013, thus predicting the current outbreaks ... has been shown to be able to predict outbreaks ...
(Date:7/30/2014)... With the accelerated aging of the ... as well as the improved medical care facilities ... industry has been developing quickly, especially in vitro ... in vitro diagnostics market size reached RMB22.98 billion, ... diagnostic reagents. , Read complete report with ...
(Date:7/30/2014)... July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... Day 180 List of Outstanding Issues (LOI) from the ... Use (CHMP) for the NB32 Marketing Authorization Application (MAA). ... an investigational drug candidate being evaluated for weight loss. ... 120 time point were adequately addressed by the Company ...
Breaking Biology Technology:Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3
... When ... has made a lasting impact on both agriculture and weed science around the globe. He ... techniques to benefit farmers. Thousands of students have followed in his footsteps and are now making ... ...
... results of this study will be presented during the ... June 3, 2009 COLUMBIA, Md., May 30 Lead ... from the University of Miami , evaluated whether ... determining rejection or infection in kidney transplant recipients. Patients ...
... and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ... of a Phase 1 trial presented during an oral ... Annual Meeting. Preliminary results as of April 2009 showed ... addition, OGX-427 demonstrated declines in circulating tumor cells at ...
Cached Biology Technology:Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 2Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 3Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 4Serial Monitoring With ImmuKnow(R) is Useful in the Risk Assessment of Kidney Transplant Recipients 2OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 2OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 3OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 4OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 5
(Date:7/30/2014)... Red Queen in Lewis Carroll,s Through the Looking ... National University of Singapore improved a 35-year-old ecology ... decades to millions of years. , The new ... incorporates the "Red Queen Effect," an evolutionary hypothesis ... which suggests that organisms must constantly increase their ...
(Date:7/30/2014)... until they hatched 4.5 years later, according to a ... PLOS ONE by Bruce Robison from Monterey ... have a single reproductive period during their life, where ... eggs until they hatch. Shallow-water octopuses typically care for ... is known about the brooding of deep-sea species. Using ...
(Date:7/30/2014)... (ACS) announced today that David L. Kaplan, Ph.D., will ... & Engineering as editor-in-chief. With the first issue ... will feature high-quality research in the rapidly burgeoning field ... materials that interact with living or biological systems. , ... tremendous growth in the field of biomaterials over the ...
Breaking Biology News(10 mins):Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3Deep-sea octopus has longest-known egg-brooding period 2ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... "Environmental Nanoparticles: Science, Ethics & Policy" on Nov. ... Center in Newark, Del. The registration deadline is ... co-sponsored by UD,s Center for Critical Zone Research ... will include presentations by nationally and internationally recognized ...
... the first critical steps in unraveling the mysteries of ... that afflicts 500,000 people worldwide each year and nearly ... An international team led by Murat Gunel, professor ... and chair of genetics, and a Howard Hughes Medical ...
... Conn. If climate disasters are to be averted, atmospheric carbon ... today, according to a study published in Open Atmospheric ... the United States, the United Kingdom and France. ... a planet similar to that on which civilization developed, an optimum ...
Cached Biology News:Workshop on environmental nanoparticles at UD, Nov. 10-11 2Yale researchers unravel mystery of brain aneurysms 2Revised theory suggests carbon dioxide levels already in danger zone 2